Combined data collated over 40 years has demonstrated that diabetes sufferers have a higher risk of developing tuberculosis (TB).

Analysing the findings of 13 different studies, involving over 1.7 million people, researchers at the Harvard School of Public Health found that diabetes increases risk of active TB three-fold.

From the results, Christie Jeon and Megan Murray suggest that diabetes may be the cause of more than ten per cent of TB cases in India and China.

Moving forward, the researchers propose that more effort diagnosing and treating diabetes may serve as an effective solution to reducing the annual number of TB-related deaths worldwide.

According to the report, published by the Public Library of Science, on a global scale, TB claims the lives of approximately 1.6 million people each year.

Earlier this month Reuters reported that the World Health Organisation predicts almost one billion people will contract TB between 2000 and 2020, 35 million of whom will die as a result.

Login and visit the Diabetes Knowledge Centre

• Study highlights lack of sleep and exercise as cancer risk 18/11/08
• Doctors warned over pre-eclampsia risk in pregnant women 05/11/08
• Yoghurt found to reduce cancer risk 17/10/08
• Gender link explored in CHD research 14/10/08
• Additional testing may improve breast cancer risk assessment 29/07/08

• TRITACE Tablets - 24.72%
  ... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ...
  
  
• TRITACE Titration Pack - 24.36%
  ... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ...
  
  
• BETAFERON - 23.54%
  ... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ...
  
  
• LOCOID Ointment - 22.5%
  The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ...
  
  
• NAGLAZYME Solution for Infusion - 22.5%
  ... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ...
  
  
• ELAPRASE Solution for Infusion - 22.5%
  Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...